Injectable Suspensions Market Manufacturers Profiles, Market Size and Market Share 2022

According to the latest research by Persistence Market Research, the injectable suspensions market is set to witness positive growth of CAGR 8.7% during 2021-2031. The injectable suspension is the mixture of solid dose drugs in a suitable liquid medium.

These are mostly prepared because the drug is insoluble in the delivery vehicle. These are used across various therapy areas like oncology, diabetes, cardiovascular diseases, dermatology, etc. These can be administrated subcutaneously or intravenously.

Due to various advantages like patient preference and ease of administration, injectable Suspensions are preferred over other methods. The injectable suspensions market is majorly driven by the rising prevalence of chronic diseases, acquisition and mergers between the companies, benefits of injectable suspensions, and approvals from the government authorities.

To remain ‘ahead’ of your competitors, request for a sample@ https://www.persistencemarketresearch.com/samples/32973

According to CDC, in U.S. 6 in 10 individuals suffer from chronic disease. These diseases are the leading cause of death globally. This acts as a driver for the injectable suspensions market. The injectable suspensions market is also driven by the increase in FDA approvals for injectable suspensions.

For instance, in 2017, FDA approved AstraZeneca’s injectable suspensions, Bydureon BCise, for the treatment of type 2 diabetes. Moreover, an increase in the awareness about the injectable suspensions and R & D investment by the companies for improving the product pipeline is expected to increase demand for injectable suspensions during the forecast period.COVID-19 had a direct and indirect impact on the injectable suspensions market. Due to sedentary lifestyles, the risk of developing chronic diseases has increased. During these pandemic times, the focus of hospitals and caregivers was shifted from controlling chronic disease to the prevention of COVID-19. Due to disruption in the supply chain, the market had an overall negative impact due to COVID-19.

Some of the leading manufacturers of injectable suspensions include,

• Merck Sharp & Dohme Corp.
• Novo Nordisk A/S
• Lilly
• Biocon Limited
• Pfizer Inc.
• BeiGene
• EnteraBio Ltd
• AbbVie Inc.
• Pfizer Limited
• Teva Pharmaceuticals USA Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Baxter International Inc.
• AstraZeneca.

The injectable suspensions market is mainly dominated by the North American region with countries like the US and Canada. The presence of major players, increase in the acquisition and mergers by the companies and FDA approvals are driving the market.For instance, in January 2021, FDA approved CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), for the treatment of HIV-1 infection.

Another region that is expected to dominate the market is Europe followed by Asia. This is due to the prevalence of chronic diseases in these regions. According to the Eurostat database, more than 1 out of 3 individuals’ aged 16 years or above is suffering from long-lasting illness. Furthermore, an increase in life science research is expected to drive the market.

Key Segments

By Route of Administration

• Intramuscular
• Subcutaneous
• Intravenous

By Indication

• Oncology
• Autoimmune disorder
• Dermatologic disorders
• Endocrine disorders
• Others

By Volume

· Small Volume Parenteral (SVP): volume

Transparency Market Research is here to provide companies a one-stop solution with regards to bettering customer experience.